New oral drugs for tuberculosis from Thiazolino-Pyridone compounds
Official title: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis
Funded at Fimbrion Therapeutics, INC. · NIH-11412466 · Data updated 2026-11-12
A small-molecule drug project seeks to develop an oral treatment for tuberculosis, including drug-resistant TB, to shorten and improve therapy.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fimbrion Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 9, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $300,000 |
| NIH project number | 5R43AI192175-02 |
| Project ID | NIH-11412466 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with active TB, including drug-resistant TB, who may benefit from new treatment options in future trials.
✕Less likely to help
Individuals without active TB or those unable to participate in early drug development studies may not benefit.
What this research studies
This program focuses on creating a new class of oral Thiazolino-Pyridone compounds that can inhibit Mycobacterium tuberculosis. The goal is to find drugs with new mechanisms of action that can be used alongside or instead of current TB medicines. Researchers will test the compounds in lab systems that model real TB infections and assess their safety and effectiveness as potential treatments. If successful, these compounds could lead to faster, more tolerable options for people with TB, including those with drug-resistant forms.
Why it matters
Potential benefit: If successful, patients could have access to a new, potentially shorter and more effective TB treatment option.
How similar studies have gone: Other TB drug discovery efforts have yielded promising new agents, though many candidates require further development before clinical use.
Where this research is happening
-
Fimbrion Therapeutics, INC.
Saint Louis, United States Active
Researchers
- Principal investigator: Jentsch, Nicholas — Fimbrion Therapeutics, INC.
- Study coordinator: Jentsch, Nicholas
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.